We are live on ! Find out more
CPHI icon

China Pharma Holdings

9 hedge funds and large institutions have $210K invested in China Pharma Holdings in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 99 (0)

0% less ownership

Funds ownership: 0.01%0% (-0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

42% less capital invested

Capital invested by funds: $362K → $210K (-$152K)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
9
Holders Change
Holders Change %
0%
% of All Funds
0.21%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
1
Increased
2
Reduced
4
Closed
1
Calls
Puts
Net Calls
Net Calls Change

CPHI Hedge Fund Activity: Q2 2018 in Review

9 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in China Pharma Holdings (CPHI) for Q2 2018, worth a combined $210K — down 42% from $362K a quarter earlier.

Fund positioning in CPHI was balanced in Q2 2018: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 4 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $1.75K. The largest seller was Citadel Advisors, cutting an estimated $24K.

  • 9 institutional investors held China Pharma Holdings (CPHI) as of Q2 2018, unchanged from Q1 2018.
  • Funds reported $210K of China Pharma Holdings stock for Q2 2018, down 42% quarter-over-quarter.
  • 1 fund opened new China Pharma Holdings positions in Q2 2018 and 1 closed out, a net change of 0 holders.
  • The largest China Pharma Holdings buyer in Q2 2018 was Susquehanna International Group, an estimated $1.75K added.
  • The largest China Pharma Holdings seller in Q2 2018 was Citadel Advisors, an estimated $24K sold.

Based on aggregated 13F filings for Q2 2018.